1. Home
  2. DXC vs STOK Comparison

DXC vs STOK Comparison

Compare DXC & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DXC Technology Company

DXC

DXC Technology Company

HOLD

Current Price

$11.97

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Logo Stoke Therapeutics Inc.

STOK

Stoke Therapeutics Inc.

HOLD

Current Price

$33.57

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DXC
STOK
Founded
1959
2014
Country
United States
United States
Employees
130000
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
2016
2019

Fundamental Metrics

Financial Performance
Metric
DXC
STOK
Price
$11.97
$33.57
Analyst Decision
Hold
Strong Buy
Analyst Count
7
10
Target Price
$15.33
$39.20
AVG Volume (30 Days)
2.1M
653.6K
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
356.52
92.73
EPS
0.88
N/A
Revenue
$12,871,000,000.00
$184,420,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$82.05
P/E Ratio
$13.28
N/A
Revenue Growth
N/A
404.50
52 Week Low
$11.54
$5.35
52 Week High
$17.68
$40.22

Technical Indicators

Market Signals
Indicator
DXC
STOK
Relative Strength Index (RSI) 43.54 49.19
Support Level $11.72 $31.60
Resistance Level $15.58 $35.75
Average True Range (ATR) 0.40 2.33
MACD 0.05 -0.40
Stochastic Oscillator 24.09 36.38

Price Performance

Historical Comparison
DXC
STOK

About DXC DXC Technology Company

DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Share on Social Networks: